Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
J Nagelschmitz, M Blunck, J Kraetzschmar… - Clinical …, 2014 - Taylor & Francis
Background The pharmacology of single doses of acetylsalicylic acid (ASA) administered
intravenously (250 or 500 mg) or orally (100, 300, or 500 mg) was evaluated in a randomized, …
intravenously (250 or 500 mg) or orally (100, 300, or 500 mg) was evaluated in a randomized, …
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative …
J Nagelschmitz, B Voith, G Wensing… - Antimicrobial agents …, 2008 - Am Soc Microbiol
In preclinical studies, artemisone (BAY 44-9585), a new artemisinin derivative, was shown
to possess enhanced efficacy over artesunate, and it does not possess the neurotoxicity …
to possess enhanced efficacy over artesunate, and it does not possess the neurotoxicity …
[HTML][HTML] Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study
H Stass, J Nagelschmitz, S Willmann, H Delesen… - Clinical drug …, 2013 - Springer
Background Oral and intravenous formulations of ciprofloxacin have established efficacy and
safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis’ …
safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis’ …
Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial
H Watz, J Nagelschmitz, A Kirsten, F Pedersen… - Pulmonary …, 2019 - Elsevier
Background There are only limited treatment options for patients with non-cystic fibrosis
bronchiectasis (non-CF BE). Human neutrophil elastase (HNE) is a mediator of tissue …
bronchiectasis (non-CF BE). Human neutrophil elastase (HNE) is a mediator of tissue …
[HTML][HTML] Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation …
H Stass, B Weimann, J Nagelschmitz… - Clinical …, 2013 - Elsevier
Background Inhaled antibacterial agents are used to manage chronic pulmonary infections
in cystic fibrosis (CF) and non-CF bronchiectasis. However, established nebulized …
in cystic fibrosis (CF) and non-CF bronchiectasis. However, established nebulized …
Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability …
R Heinig, M Gerisch, A Engelen, J Nagelschmitz… - European Journal of …, 2018 - Springer
Background and Objectives Finerenone is a selective, non-steroidal mineralocorticoid receptor
antagonist. In vivo and in vitro studies were performed to assess absolute bioavailability …
antagonist. In vivo and in vitro studies were performed to assess absolute bioavailability …
[HTML][HTML] Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
…, T Marquardt, T Mondritzki, J Nagelschmitz… - Respiratory …, 2022 - Springer
Background Oxidative stress associated with severe cardiopulmonary diseases leads to
impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native …
impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native …
Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study
H Stass, H Delesen, J Nagelschmitz… - Journal of aerosol …, 2015 - liebertpub.com
Background: Reliable, reproducible deposition to the lung is a major prerequisite for the
clinical use of inhaled drugs. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI; Bayer …
clinical use of inhaled drugs. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI; Bayer …
Results from drug–drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications
R Heinig, M Gerisch, M Bairlein, J Nagelschmitz… - European Journal of …, 2020 - Springer
Background and Objectives In vivo studies were performed with the novel, selective, non-steroidal
mineralocorticoid receptor antagonist finerenone to assess the relevance of inductive …
mineralocorticoid receptor antagonist finerenone to assess the relevance of inductive …
Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment
R Heinig, M Lambelet, J Nagelschmitz… - European Journal of …, 2019 - Springer
Background and Objectives Finerenone (BAY 94-8862) is a selective, nonsteroidal
mineralocorticoid receptor antagonist. The aim of this study was to assess the effect of mild or …
mineralocorticoid receptor antagonist. The aim of this study was to assess the effect of mild or …